KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Work In Process: 2009-2018

Historic Work In Process for Teva Pharmaceutical Industries (TEVA) over the last 1 years, with Dec 2018 value amounting to $590.0 million.

  • Teva Pharmaceutical Industries' Work In Process fell 1.17% to $590.0 million in Q4 2018 from the same period last year, while for Dec 2018 it was $590.0 million, marking a year-over-year decrease of 1.17%. This contributed to the annual value of $590.0 million for FY2018, which is 1.17% down from last year.
  • Teva Pharmaceutical Industries' Work In Process amounted to $590.0 million in Q4 2018, which was down 3.12% from $609.0 million recorded in Q3 2018.
  • Teva Pharmaceutical Industries' Work In Process' 5-year high stood at $646.0 million during Q1 2018, with a 5-year trough of $535.0 million in Q4 2015.
  • In the last 3 years, Teva Pharmaceutical Industries' Work In Process had a median value of $601.0 million in 2017 and averaged $597.5 million.
  • Its Work In Process has fluctuated over the past 5 years, first declined by 16.14% in 2015, then climbed by 10.97% in 2017.
  • Teva Pharmaceutical Industries' Work In Process (Quarterly) stood at $638.0 million in 2014, then decreased by 16.14% to $535.0 million in 2015, then increased by 0.56% to $538.0 million in 2016, then grew by 10.97% to $597.0 million in 2017, then fell by 1.17% to $590.0 million in 2018.
  • Its last three reported values are $590.0 million in Q4 2018, $609.0 million for Q3 2018, and $605.0 million during Q2 2018.